Citius Oncology (CTOR) Change in Accured Expenses (2023 - 2026)
Citius Oncology (CTOR) posted quarterly Change in Accured Expenses of $19.5 million for Q1 2026, up 683.57% year-over-year from $2.5 million in Q1 2025, and up 4488.78% quarter-over-quarter from $425792.0 in Q4 2025.
Citius Oncology (CTOR) Change in Accured Expenses (2023 - 2026) Analysis & Trends
Citius Oncology (CTOR) has reported Change in Accured Expenses for 4 consecutive years, with $19.5 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Change in Accured Expenses rose 683.57% year-over-year to $19.5 million; the TTM figure through Mar 2026 stood at $15.3 million (up 77.31% YoY), while the FY2025 annual figure was $4.1 million, up 1679.92% from the prior year.
- Change in Accured Expenses improved to $19.5 million in Q1 2026 per CTOR's latest filing, from $425792.0 in the prior quarter.
- Across five years, Change in Accured Expenses topped out at $19.5 million in Q1 2026 and bottomed at -$4.4 million in Q3 2025.
- Historically, Change in Accured Expenses has averaged $2.0 million across 4 years, with a median of $126025.0 in 2023.
- On a YoY basis, Change in Accured Expenses climbed as much as 3227.52% in 2024 and fell as far as 1724.88% in 2024.
- Citius Oncology's Change in Accured Expenses stood at -$199155.0 in 2023, then soared by 3227.52% to $6.2 million in 2024, then tumbled by 93.16% to $425792.0 in 2025, then surged by 4488.78% to $19.5 million in 2026.
- Business Quant data shows CTOR's Change in Accured Expenses at $19.5 million in Q1 2026, $425792.0 in Q4 2025, and -$4.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.51 Bn | 43.55 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.52 Bn | 39.86 Bn | 2.15 Bn | 82.00 Mn |
| 3 | Zoetis | 32.43 Bn | 30.75 Bn | 1.05 Bn | 142.00 Mn |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn | -219.00 Mn |
| 5 | United Therapeutics | 21.87 Bn | 19.21 Bn | 683.80 Mn | -4.00 Mn |
| 6 | Viatris | 18.98 Bn | 18.09 Bn | 1.46 Bn | - |
| 7 | Neurocrine Biosciences | 15.43 Bn | 15.04 Bn | 935.80 Mn | -8.50 Mn |
| 8 | Elanco Animal Health | 12.02 Bn | 11.49 Bn | 798.00 Mn | - |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - | - |
| 10 | Citius Oncology | 79.23 Mn | 79.23 Mn | 1.00 Mn | 16,047.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 19.54 Mn |
| Mar 31, 2026 | 19.54 Mn |
| Dec 31, 2025 | 425,792.00 |
| Dec 31, 2025 | 425,792.00 |
| Sep 30, 2025 | -4.37 Mn |
| Sep 30, 2025 | -4.37 Mn |
| Jun 30, 2025 | -263,614.00 |
| Jun 30, 2025 | -263,614.00 |
| Mar 31, 2025 | 2.49 Mn |
| Mar 31, 2025 | 2.49 Mn |
| Dec 31, 2024 | 6.23 Mn |
| Dec 31, 2024 | 6.23 Mn |
| Jun 30, 2024 | 185,930.00 |
| Jun 30, 2024 | 185,930.00 |
| Mar 31, 2024 | -259,071.00 |
| Mar 31, 2024 | -259,071.00 |
| Dec 31, 2023 | -199,155.00 |
| Dec 31, 2023 | -199,155.00 |
| Sep 30, 2023 | 356,868.00 |
| Sep 30, 2023 | 356,868.00 |